Your session is about to expire
← Back to Search
Autogene Cevumeran + Atezolizumab + Chemotherapy for Pancreatic Cancer (IMCODE003 Trial)
IMCODE003 Trial Summary
This trial evaluates the safety & efficacy of a combo treatment for pancreatic cancer after surgery to see if it's better than a single treatment.
IMCODE003 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.IMCODE003 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My diagnosis of pancreatic cancer is confirmed through tissue examination.It has been 6 to 12 weeks since my pancreatic cancer surgery.I have had initial treatment for pancreatic cancer.My pancreatic cancer was completely removed with surgery.My blood and organs are functioning well.I do not have a spleen and have not had a distal pancreatectomy with splenectomy.My doctor confirmed I have no signs of cancer after surgery.I have or had an autoimmune disease or immune deficiency.My pancreatic cancer is in the early or middle stages, without distant spread.I have fully recovered from surgery and can receive specific cancer treatments as per my doctor's judgment.I will avoid fathering a child or donate sperm during and for 6 months after treatment.
- Group 1: Arm 1: Autogene Cevumeran + Atezolizumab + mFOLFIRINOX
- Group 2: Arm 2: mFOLFIRINOX
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA sanctioned a combination of Autogene Cevumeran, Atezolizumab and mFOLFIRINOX for Arm 1?
"Arm 1: Autogene Cevumeran + Atezolizumab + mFOLFIRINOX obtained a score of 2 since Phase 2 trials have only provided evidence regarding the safety but not efficacy."
What is the enrollment size of this medical study?
"Affirmative, the information on clinicialtrials.gov implies that this clinical trial is in search of volunteers. It was initially posted at 22nd July 2023 and subsequently updated on 21st July 2023. This study requires 260 individuals to be recruited from 1 centre."
Is this research initiative recruiting participants?
"Indeed, the information found on clinicaltrials.gov demonstrates that this medical trial is actively recruiting participants. This experiment was initially published on July 22nd 2023 and last updated on July 21st 2023. The study requires 260 volunteers from one location to be enrolled in order for it to continue forward."
Share this study with friends
Copy Link
Messenger